Details - Clinical Research

Clinical Research Details

Back to List

Descriptive Information

Title

A randomized , double blind, multicenter, phase III study of Everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin

Investigator Name

Ali Shamseddine

as04@aub.edu.lb

Protocol Id

CRAD001T2302

Status

Ongoing

Study Type

Clinical Research - Clinical Trials (phase 0, 1,2 3 & 4)

Phase

Phase 3

Looking for Med Students Volunteers

Sponsors

Novartis

Conditions and Keywords

Conditions

Advanced Neuroendocrine tumors of GI or lung origin

Keywords

Neurodendocrine tumors, Everolimus, GI, Lung

Study Design

Primary Purpose

Treatment

Classification

Safety and/or Efficacy Study

Time Perspective

Prospective

Masking

Double Blind

Intervention Model

Parallel-Group

Allocation

Randomized

Eligibility and IRB

Gender

Both

Age Limits

Min: 18

Max:

IRB Approval

Yes

Healthy Volunteer

Study Description

Population Description

Sampling Method

Inclusion Criteria

Adult patients with histologically confirmed advanced low and intermediate grade nonfunctional NET of GI or lung origin with measurable disease at baseline whose disease progressed within the past six months

Exclusion Criteria

Patients with a history of carcinoid syndrome and/or active symptoms of carcinoid at the time of screening are excluded. Poorly differentiated/high grade tumors are excluded.

Back to List